Settlement Agreement

On October 14, 2021 Purple Biotech Ltd. (the "Registrant" or the "Company") reported that the Company entered into a settlement agreement with Lupin Ltd. and its subsidiary Lupin Pharmaceuticals, Inc. (collectively, "Lupin"), resolving the Company’s patent litigation against Lupin (Press release, Purple Biotech, OCT 14, 2021, View Source [SID1234591220]). The litigation concerned Lupin’s filing of an Abbreviated New Drug Application (ANDA) seeking approval from the U.S. Food and Drug Administration (FDA) to market a generic version of the Company’s commercial drug CONSENSI. This agreement with Lupin allows Lupin to enter the market on March 1, 2030 and earlier, under certain circumstances.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!